HUMIRA treats a number of autoimmune conditions.

HUMIRA (adalimumab) helps treat the pain and inflammation of certain autoimmune conditions and could be right for you if you still have symptoms despite your current treatment.

HUMIRA Safety Information

Safety information on this website includes some of the more important information to know about HUMIRA.

Read More 

How does HUMIRA work?

HUMIRA is a fully human monoclonal antibody. HUMIRA recognises and binds to a specific protein (tumour necrosis factor or TNF-alpha), which is present at increased levels in inflammatory diseases such as Rheumatoid Arthritis.

Read More 

Starting and taking HUMIRA

What you need to know about taking HUMIRA, including free support to help you get the best out of your HUMIRA treatment.

Read More 

 

  • *AbbVie medications and programmes are designed to support patients on their health journey.
  • References:
  1. HUMIRA Consumer Medicine Information

This site is intended for a New Zealand audience.

Important information about HUMIRA. HUMIRA is a prescription medicine containing adalimumab. HUMIRA is available as a single use, pre-filled syringe (containing 20mg or 40mg adalimumab) or single-use, pre-filled pen (containing 40mg adalimumab). It is used in the treatment of patients with rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, chronic plaque psoriasis, ulcerative colitis, Crohn’s disease, non-infectious uveitis, and hidradenitis suppurativa. HUMIRA is only used in patients of a specific age group, in diseases of certain severity (e.g. moderate to severe), and/or after some other treatments have been tried (e.g. conventional therapy).

HUMIRA has risks and benefits. Refer to the Safety Information contained on this website for further details. If you have any questions about using HUMIRA, ask your healthcare professional and refer to the Consumer Medicine Information (CMI) available here: HUMIRA PEN CMI or HUMIRA Pre-filled Syringe CMI or by calling freephone 0800 900 030. Ask your doctor if HUMIRA is right for you. Use strictly as directed. If symptoms continue, or you have side effects, see your doctor, pharmacist or healthcare professional.

HUMIRA is a fully funded medicine under Special Authority for most indications - normal pharmacy prescription charges apply. HUMIRA is not funded for enthesitis-related arthritis, non-radiographic axial spondyloarthritis and ulcerative colitis – a pharmacy charge will apply. Normal doctor’s charges apply.

AbbVie is the company that brings you HUMIRA (adalimumab). For more information about AbbVie, visit www.AbbVie.co.nz | HUMIRA Data Sheet

AbbVie Limited, 6th floor, 156-158 Victoria street, Wellington, 6011, New Zealand 0800 900 030. HUMIRA and Destination You are registered trademarks of AbbVie Biotechnology Ltd.

NZ-HUM-200011. TAPS PP5546. Last updated: July 2020. Copyright © AbbVie Limited.

 

Debug Window